Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

AngioDynamics stock

ANGO
US03475V1017
A0B9A5

Price

7.78
Today +/-
+0.11
Today %
+1.55 %
P

AngioDynamics stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the AngioDynamics stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the AngioDynamics stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the AngioDynamics stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze AngioDynamics's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

AngioDynamics Stock Price History

DateAngioDynamics Price
9/30/20247.78 undefined
9/27/20247.66 undefined
9/26/20247.51 undefined
9/25/20247.40 undefined
9/24/20247.58 undefined
9/23/20247.50 undefined
9/20/20247.54 undefined
9/19/20247.70 undefined
9/18/20247.60 undefined
9/17/20247.64 undefined
9/16/20247.51 undefined
9/13/20247.64 undefined
9/12/20247.51 undefined
9/11/20247.42 undefined
9/10/20247.39 undefined
9/9/20247.25 undefined
9/6/20247.17 undefined
9/5/20247.36 undefined
9/4/20247.33 undefined
9/3/20247.32 undefined

AngioDynamics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into AngioDynamics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by AngioDynamics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects AngioDynamics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of AngioDynamics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into AngioDynamics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing AngioDynamics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on AngioDynamics’s growth potential.

AngioDynamics Revenue, EBIT and net profit per share

DateAngioDynamics RevenueAngioDynamics EBITAngioDynamics Net Income
2028e395.98 M undefined0 undefined22.6 M undefined
2027e351.04 M undefined-204,000 undefined10.27 M undefined
2026e314.48 M undefined-13.36 M undefined-4.72 M undefined
2025e290.05 M undefined-28.97 M undefined-16.71 M undefined
2024303.91 M undefined-34.28 M undefined-184.35 M undefined
2023338.8 M undefined-21 M undefined-52.4 M undefined
2022316.2 M undefined-19.5 M undefined-26.5 M undefined
2021291 M undefined-15.1 M undefined-31.5 M undefined
2020264.2 M undefined-2.5 M undefined-166.8 M undefined
2019270.6 M undefined5.7 M undefined61.3 M undefined
2018261.7 M undefined1.2 M undefined16.3 M undefined
2017269.8 M undefined16.3 M undefined5 M undefined
2016353.9 M undefined13.6 M undefined-43.6 M undefined
2015356.5 M undefined22.9 M undefined-3.4 M undefined
2014354.4 M undefined21.4 M undefined2.3 M undefined
2013341.9 M undefined20.1 M undefined-1.2 M undefined
2012221.9 M undefined12 M undefined-5.2 M undefined
2011215.8 M undefined19.2 M undefined8.1 M undefined
2010216 M undefined20.9 M undefined12.3 M undefined
2009195.1 M undefined16.1 M undefined9.9 M undefined
2008166.5 M undefined19.8 M undefined10.9 M undefined
2007112.2 M undefined-1.5 M undefined-9.1 M undefined
200678.5 M undefined10.3 M undefined6.9 M undefined
200560.3 M undefined7.7 M undefined4.5 M undefined

AngioDynamics Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
2001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025e2026e2027e2028e
233038496078112166195216215221341354356353269261270264291316338303290314351395
-30.4326.6728.9522.4530.0043.5948.2117.4710.77-0.462.7954.303.810.56-0.84-23.80-2.973.45-2.2210.238.596.96-10.36-4.298.2811.7812.54
47.8350.0050.0051.0255.0057.6958.9361.4561.5458.8058.1456.5649.2750.8549.1649.2953.5354.7957.7856.8253.6152.2251.4850.83----
111519253345661021201271251251681801751741441431561501561651741540000
0235710-11916201912202122131615-2-15-19-21-34-28-1300
-6.677.8910.2011.6712.82-0.8911.458.219.268.845.435.875.936.183.685.950.381.85-0.76-5.15-6.01-6.21-11.22-9.66-4.14--
011346-9109128-5-12-3-4351661-166-31-26-52-184-16-41022
---200.0033.3350.00-250.00-211.11-10.0033.33-33.33-162.50-80.00-300.00-250.001,333.33-111.63220.00281.25-372.13-81.33-16.13100.00253.85-91.30-75.00-350.00120.00
9.29.39.59.812.31318.424.324.524.825.125.434.835.435.736.236.637.137.53838.33939.540.180000
----------------------------
Details

Keystats

ⓘ

Revenue and Growth

The AngioDynamics Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the AngioDynamics is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (k)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
20022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024
                                             
2.81.72.527.189.871.578.268.2100.1131.537.62821.322.13448.875.4227.654.45130.945.576.97
4.56.57.91013.520.826.627.229.827.148.647.86258.452.944.539.443.631.335.452.352.843.61
002000000002.500000002.90006.4
7.98.68.510.3162822.936.929.228.155.855.161.267.455.454.548.940.159.948.651.455.360.62
0.71.71.52.32.9714.116.312.37.514.710.77.22.946.24.344.45.98.79.95.66
15.918.540.449.7122.2127.3141.8148.6171.4194.2159.2141.6151.7150.8146.3154168315.3152.9140.9143.3163.5193.25
2.76.37.38.510.816.821.222.224.223.855.962.766.654.548.345.242.524.338.546.55249.541.47
00000000000000000000000
00000000000000000000000
1.2110.83.649.171.367.858.448147.3214.8205.3181.7166.6145.7130.3145.4197.1169152.4111.177.38
00000153.8162.7162162162308.9355.5360.5361.3361.3361.3361.3347.7200.5201.3201.1159.20
0.91.210.60.536.211.78.289.350.417.114.924.93.81.93.43.85.23.8449.25.57
4.88.59.39.914.9255.9266.9260.2252.6243.1562.5650.1647.3622.4580554.1537.5521.2441.3420.6409.5369124.42
20.72749.759.6137.1383.2408.7408.8424437.3721.7791.7799773.2726.3708.1705.5836.5594.2561.5552.8532.5317.67
                                             
0100100100200200200200200300300400400400400400400400400400400400385
11.812.645.552.9120.2341.8350.6358365.3371.4496.4500.6508.4520.1525.8532.7543.8555561.9573.5586.9599.2610.48
-12.1-10.9-8.3-3.73.1-64.914.827.235.330.229.631.527.6-16-115.166.5-100.3-131.9-158.4-210.9-395.2
0-0.3-0.1-0.2-0.1-0.10-0.9-1.4-1.3-1.3-1.5-1.3-0.8-0.8-1.30.1-1.4-1.33.21.4-4.7-4.37
0000000000000000-1000000
-0.31.537.249.1123.4335.9355.7372.1391.3405.7525.6529.1539547.3509.4520.8548.4620.5460.7445.2430.3384211.3
2.942.845.87.69.113.21211.429.224.532.92315.618.115.822.819.119.62840.437.75
1.92.13.33.54.88.19.511.113.713.818.715.916.717.921.938.834.438.331.537.937.428.536.81
000.1004.412.75.200015.512.210.912.99.62.14.60.90.18.914.816.59
00000000000000000000000
10.13.20.20.20.3100.30.30.37.57.558.816.3557.500000
5.86.29.47.710.820.441.329.82625.555.463.466.860.666.771.557.373.251.557.674.383.791.16
15.219.43.12.92.817.17.16.86.66.3142.5135137.7128.9104.391.386.6124.440202549.80
0000000000001.11.121.726.117.214.524.1201612.84.85
000009.84.60000.366.356.537.426.341.89.423.824.412.97.916.08
15.219.43.12.92.826.911.76.86.66.3142.8201.3195.3167.4152.3121.4105.6148.387.964.453.970.520.93
2125.612.510.613.647.35336.632.631.8198.2264.7262.1228219192.9162.9221.5139.4122128.2154.2112.09
20.727.149.759.7137383.2408.7408.7423.9437.5723.8793.8801.1775.3728.4713.7711.3842600.1567.2558.5538.2323.39
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of AngioDynamics provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand AngioDynamics's financial health and stability.

Assets

AngioDynamics's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that AngioDynamics must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of AngioDynamics after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into AngioDynamics's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (k)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
20012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
011346-9109128-5-12-3-4351661-166-31-26-52
00000139111212142728302824232523252930
-100000-25450002-5394-8-2-1-4-3-2
00-2-2-2-70-8-653-3-9-13-1012242-1-289-21-7
0000221696814101492111216-36166342542
00000000000043332350002
00000211240200000000000
0102438251939331126242645554137-1424-70
00-4-1-1-6-31-25-21-10-4-3-12-12-13-5-3-3-3-7-5-4-4
10-4-1-13-19-55-26-15-11-48-176-22-16-13-7-2-382-63-13-19-9
1000-11-13-2305-1-44-173-9-30-10085-55-8-15-5
00000000000000000000000
-103016040-1000143-70-5-16-23-540-92-20525
00005654412211252-2220321
-10302165104-821142-6-14-10-23-37-1133-95-16725
0000001,0000000-2,0000-16,000-11,000-9,000-11,000-9,000-8,000-1,000000
00000000000000000000000
00001249-353-430-12-22-1-52131526153-173-6-1915
-0.060.53-3.380.812.96-2.86-22.270.5-1.529.5129.838.5613.7312.0712.9539.6352.7537.6334.32-22.1418.9-11.49-4.27
00000000000000000000000

AngioDynamics stock margins

The AngioDynamics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of AngioDynamics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for AngioDynamics.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the AngioDynamics's sales revenue. A higher gross margin percentage indicates that the AngioDynamics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the AngioDynamics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the AngioDynamics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the AngioDynamics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the AngioDynamics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the AngioDynamics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

AngioDynamics Margin History

AngioDynamics Gross marginAngioDynamics Profit marginAngioDynamics EBIT marginAngioDynamics Profit margin
2028e50.9 %0 %5.71 %
2027e50.9 %-0.06 %2.93 %
2026e50.9 %-4.25 %-1.5 %
2025e50.9 %-9.99 %-5.76 %
202450.9 %-11.28 %-60.66 %
202351.42 %-6.2 %-15.47 %
202252.4 %-6.17 %-8.38 %
202153.88 %-5.19 %-10.82 %
202056.89 %-0.95 %-63.13 %
201957.65 %2.11 %22.65 %
201854.99 %0.46 %6.23 %
201753.37 %6.04 %1.85 %
201649.25 %3.84 %-12.32 %
201549.31 %6.42 %-0.95 %
201450.85 %6.04 %0.65 %
201349.28 %5.88 %-0.35 %
201256.47 %5.41 %-2.34 %
201158.25 %8.9 %3.75 %
201058.8 %9.68 %5.69 %
200961.56 %8.25 %5.07 %
200861.62 %11.89 %6.55 %
200759 %-1.34 %-8.11 %
200657.96 %13.12 %8.79 %
200555.39 %12.77 %7.46 %

AngioDynamics Stock Sales Revenue, EBIT, Earnings per Share

The AngioDynamics earnings per share therefore indicates how much revenue AngioDynamics has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue AngioDynamics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates AngioDynamics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of AngioDynamics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating AngioDynamics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

AngioDynamics Revenue, EBIT and net profit per share

DateAngioDynamics Sales per ShareAngioDynamics EBIT per shareAngioDynamics Earnings per Share
2028e9.83 undefined0 undefined0.56 undefined
2027e8.71 undefined0 undefined0.26 undefined
2026e7.81 undefined0 undefined-0.12 undefined
2025e7.2 undefined0 undefined-0.41 undefined
20247.56 undefined-0.85 undefined-4.59 undefined
20238.58 undefined-0.53 undefined-1.33 undefined
20228.11 undefined-0.5 undefined-0.68 undefined
20217.6 undefined-0.39 undefined-0.82 undefined
20206.95 undefined-0.07 undefined-4.39 undefined
20197.22 undefined0.15 undefined1.63 undefined
20187.05 undefined0.03 undefined0.44 undefined
20177.37 undefined0.45 undefined0.14 undefined
20169.78 undefined0.38 undefined-1.2 undefined
20159.99 undefined0.64 undefined-0.1 undefined
201410.01 undefined0.6 undefined0.06 undefined
20139.82 undefined0.58 undefined-0.03 undefined
20128.74 undefined0.47 undefined-0.2 undefined
20118.6 undefined0.76 undefined0.32 undefined
20108.71 undefined0.84 undefined0.5 undefined
20097.96 undefined0.66 undefined0.4 undefined
20086.85 undefined0.81 undefined0.45 undefined
20076.1 undefined-0.08 undefined-0.49 undefined
20066.04 undefined0.79 undefined0.53 undefined
20054.9 undefined0.63 undefined0.37 undefined

AngioDynamics business model

AngioDynamics Inc is a leading provider of medical devices and solutions for the treatment of vascular diseases and cancer. The company was founded in 1988 and is headquartered in Latham, New York. Over the years, AngioDynamics has evolved into a conglomerate through several acquisitions and partnerships, specializing in various areas. The key divisions include Vascular Access Solutions, Oncology Solutions, and Peripheral Vascular Solutions. AngioDynamics focuses on developing and manufacturing innovative technologies that improve medical care and promote patient health. The company develops and distributes a wide range of medical devices and procedures to treat diseases such as cancer, venous diseases, and thrombosis. In the Vascular Access Solutions division, AngioDynamics offers a wide range of devices for establishing vascular access, which are necessary for the treatment of serious illnesses. This includes port systems and catheters that facilitate access to the body's vascular system. AngioDynamics' Oncology Solutions provide targeted cancer treatment options, including ultrasound-controlled radiofrequency ablation systems and fusion biopsy systems. The development of innovative diagnostic and treatment options is a focus of AngioDynamics. A majority of AngioDynamics' products are in the Peripheral Vascular Solutions division. Here, the company develops devices and procedures for the treatment of peripheral vascular diseases such as varicose veins or chronic venous insufficiency. This includes procedures like laser and radiofrequency treatments that can be performed minimally invasively. AngioDynamics has gained an excellent reputation in the medical industry due to its high-quality products, innovative technologies, and close collaboration with medical professionals. The company places great emphasis on providing optimal care to every patient and therefore serves hospitals, clinics, and medical practices worldwide. Over the years, AngioDynamics has become a leading provider of medical devices and solutions for the treatment of vascular diseases and cancer. The company has built a broad customer base worldwide and has become an important player in the medical industry due to the quality and innovation of its products. AngioDynamics is one of the most popular companies on Eulerpool.com.

AngioDynamics Revenue by Segment

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

AngioDynamics Revenue by Segment

Segmente202420232022202120202019201820172016201520142013
Vascular Access--100.19 M USD101.31 M USD94.3 M USD15.12 M USD------
Endovascular Therapies--160.93 M USD135.08 M USD--------
Med Device--237.5 M USD---------
Oncology--55.1 M USD54.62 M USD57.15 M USD25.42 M USD------
Med Tech106.4 M USD-78.72 M USD---------
Vascular Interventions & Therapies----112.71 M USD13.13 M USD------
Peripheral Vascular-------208.6 M USD202.78 M USD192.83 M USD192.66 M USD188.18 M USD
Oncology/Surgery--55.1 M USD54.62 M USD57.15 M USD56 M USD-44.56 M USD48.9 M USD52.09 M USD49.36 M USD47.16 M USD
Med Device197.51 M USD242.07 M USD----------
Vascular Access----94.3 M USD94.73 M USD-96.48 M USD99.38 M USD---
Access---------107.87 M USD106.39 M USD106.69 M USD
Endovascular Therapies--160.93 M USD135.08 M USD--------
Vascular-----------294.87 M USD
Vascular Interventions & Therapies----112.71 M USD119.9 M USD------
Med Tech-96.69 M USD----------
Supply Agreement--------2.84 M USD4.18 M USD6.05 M USD-
Peripheral Vascular------202.33 M USD-----
Vascular Access------92.76 M USD-----
Oncology/Surgery------49.19 M USD-----

AngioDynamics Revenue by Region

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Region

The chart shows revenues by region and provides a clear comparison of regional revenue distribution. Each region is clearly marked to illustrate the differences.

Interpretation and Usage

The diagram helps to identify the regions with the highest revenue and to make targeted decisions for regional expansion or investments. It supports the analysis of market potentials and strategic priorities.

Investment Strategy

An investment strategy focused on regions concentrates on the deliberate capital allocation in different markets to optimally use regional growth opportunities. It takes into account market conditions and regional risk factors.

AngioDynamics Revenue by Segment

DateInternationalUnited States
202452.43 M USD251.49 M USD
202356.04 M USD282.71 M USD
202250.26 M USD265.96 M USD
202153.97 M USD237.04 M USD
202056.18 M USD207.98 M USD
201953.68 M USD216.96 M USD
201870.96 M USD273.33 M USD
201767.48 M USD282.17 M USD
201667.53 M USD283.52 M USD
201571.95 M USD280.85 M USD
201468.22 M USD280.19 M USD
201367.19 M USD274.84 M USD

AngioDynamics SWOT Analysis

Strengths

1. Strong market presence: AngioDynamics Inc has established a strong presence in the medical device industry, particularly in the field of minimally invasive therapeutic and diagnostic technologies.

2. Diverse product portfolio: The company offers a wide range of innovative medical devices, including vascular access products, vascular interventions, angiographic products, and oncology systems, which cater to various healthcare needs.

3. Technological advancements: AngioDynamics Inc invests heavily in research and development to ensure continuous innovation and technological advancements in its products, enabling it to stay ahead of competitors.

4. Strong financial position: The company has demonstrated strong financial performance, with steady revenue growth and healthy profit margins, providing a solid foundation for future investments and expansion.

Weaknesses

1. Dependence on a limited customer base: AngioDynamics Inc heavily relies on a few key customers, which can pose a risk if any of them significantly reduce or terminate their business relationships with the company.

2. Regulatory challenges: The medical device industry is subject to strict regulations and compliance requirements, and any non-compliance can result in product delays or recalls, impacting the company's reputation and financial performance.

3. Limited global presence: While the company has a solid market presence in the United States, its international market penetration is relatively limited, which restricts its growth potential in global markets.

4. Intense competition: AngioDynamics Inc faces intense competition from both established medical device companies and emerging startups, which may result in price pressure and difficulty in maintaining market share.

Opportunities

1. Growing demand for minimally invasive procedures: There is an increasing trend towards minimally invasive surgeries and treatments, presenting an opportunity for AngioDynamics Inc to expand its market share in this rapidly growing segment.

2. Expansion into emerging markets: The company can capitalize on the growing healthcare infrastructure in emerging markets by expanding its global presence and partnering with local distributors or healthcare providers.

3. Strategic collaborations and acquisitions: AngioDynamics Inc can explore strategic collaborations or acquisitions to enhance its product portfolio, gain access to new technologies, and expand its customer base.

4. Focus on oncology market: The rising prevalence of cancer and increasing adoption of minimally invasive treatments in oncology create opportunities for the company to develop specialized products and solutions catering to this market segment.

Threats

1. Economic downturns: Any economic downturn or financial crisis can impact healthcare spending, leading to a decrease in demand for medical devices and potentially affecting AngioDynamics Inc's sales and revenue.

2. Stringent regulatory environment: The medical device industry is subject to evolving and complex regulations, and compliance failures can lead to penalties, product recalls, or a halt in manufacturing, which may affect the company's operations and financial performance.

3. Price pressure from competitors: Intense competition within the industry can result in price wars and reduced profit margins, especially if competitors offer similar products at lower prices, posing a threat to AngioDynamics Inc's market position.

4. Technological obsolescence: Rapid advancements in technology and medical innovations could render existing products obsolete, necessitating continuous investments in research and development to stay ahead of market trends.

AngioDynamics Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

AngioDynamics historical P/E ratio, EBIT multiple, and P/S ratio

AngioDynamics shares outstanding

The number of shares was AngioDynamics in 2023 — This indicates how many shares 39.5 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue AngioDynamics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates AngioDynamics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of AngioDynamics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating AngioDynamics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Unfortunately, there are currently no price targets and forecasts available for AngioDynamics.

AngioDynamics latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/2024-0.17 -0.06  (64.71 %)2024 Q4
3/31/2024-0.14 -0.16  (-15.94 %)2024 Q3
12/31/2023-0.08 -0.05  (34.64 %)2024 Q2
9/30/2023-0.13 -0.12  (9.5 %)2024 Q1
6/30/20230.02 0.02  (-12.66 %)2023 Q4
3/31/2023-0.01 -0.03  (-289.61 %)2023 Q3
12/31/2022-0.01 0.01  (198.04 %)2023 Q2
9/30/2022-0.02 -0.06  (-162.01 %)2023 Q1
6/30/20220.01 0.01  (29.87 %)2022 Q4
3/31/2022-0.01 0.03  (334.38 %)2022 Q3
1
2
3
4
5
...
9

Eulerpool ESG Scorecard© for the AngioDynamics stock

Eulerpool World ESG Rating (EESG©)

35/ 100

🌱 Environment

8

👫 Social

40

🏛️ Governance

56

Environment

Scope 1 - Direct Emissions
—
Scope 2 - Indirect emissions from purchased energy
—
Scope 3 - Indirect emissions within the value chain
—
Total CO₂ emissions
—
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
❌
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
❌
Environmentally friendly packaging
❌
Hazardous substances
❌
Fuel consumption and efficiency
❌
Water consumption and efficiency
❌

Social

Percentage of female employees—
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept✅
Privacy concept—
Occupational health and safety✅
Catholic✅

Governance (Corporate Governance)

Environmental reporting❌
Stakeholder Engagement❌
Call Back Policies❌
Antitrust law❌

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

AngioDynamics shareholders

%
Name
Stocks
Change
Date
9.07852 % BlackRock Institutional Trust Company, N.A.3,656,828424,88912/31/2023
5.63173 % The Vanguard Group, Inc.2,268,461141,96512/31/2023
4.79681 % Systematic Financial Management, L.P.1,932,15431,37412/31/2023
4.55754 % Millennium Management LLC1,835,777-861,89412/31/2023
4.21324 % Morgan Stanley & Co. LLC1,697,093766,66212/31/2023
3.69689 % Dimensional Fund Advisors, L.P.1,489,108-181,63512/31/2023
3.34015 % Two Sigma Investments, LP1,345,413-141,86212/31/2023
2.61674 % Assenagon Asset Management S.A.1,054,022012/31/2023
2.53031 % BlackRock Financial Management, Inc.1,019,207458,38312/31/2023
2.51682 % Citadel Advisors LLC1,013,7763,57912/31/2023
1
2
3
4
5
...
10

AngioDynamics Executives and Management Board

Mr. James Clemmer59
AngioDynamics President, Chief Executive Officer, Director (since 2016)
Compensation 3.98 M
Mr. Stephen Trowbridge49
AngioDynamics Chief Financial Officer, Executive Vice President
Compensation 1.25 M
Ms. Laura Piccinini54
AngioDynamics Senior Vice President, General Manager - International
Compensation 843,436
Mr. Scott Centea45
AngioDynamics Senior Vice President, General Manager - Endovasular Therapies (since 2020)
Compensation 841,368
Mr. Chad Campbell52
AngioDynamics Senior Vice President, General Manager - Vascular Access and Oncology
Compensation 778,036
1
2
3

Most common questions regarding AngioDynamics

What values and corporate philosophy does AngioDynamics represent?

AngioDynamics Inc represents values of innovation, patient focus, and commitment to improving medical treatments. The company's corporate philosophy revolves around developing and delivering breakthrough medical technologies that enhance patient care and improve the quality of life. AngioDynamics is dedicated to providing innovative solutions for minimally invasive, image-guided medical procedures, with a focus on delivering superior outcomes for patients. With a strong emphasis on research and development, AngioDynamics continuously strives to advance medical technologies, ensuring patient safety, and revolutionizing the field of medical interventions.

In which countries and regions is AngioDynamics primarily present?

AngioDynamics Inc is primarily present in the United States.

What significant milestones has the company AngioDynamics achieved?

AngioDynamics Inc has achieved several significant milestones throughout its existence. One notable accomplishment includes the development and commercialization of innovative medical devices for the treatment of peripheral vascular disease and cancer. The company has also expanded its global presence by successfully introducing its products in various international markets. Furthermore, AngioDynamics Inc has received numerous accolades and recognition for its breakthrough technologies, including the FDA approval of its groundbreaking radiofrequency ablation system. With a steadfast commitment to improving patient outcomes, AngioDynamics Inc continues to make strides in the field of medical technology and remains at the forefront of innovation.

What is the history and background of the company AngioDynamics?

AngioDynamics Inc. is a leading medical technology company specializing in the development and manufacture of innovative medical devices used in minimally invasive procedures. The company was founded in 1988 and is headquartered in Latham, New York. AngioDynamics Inc. has a rich history of delivering cutting-edge solutions in areas such as vascular access, peripheral vascular disease, and oncology. With a commitment to improving patient outcomes, AngioDynamics Inc. has established itself as a trusted provider of advanced medical devices to healthcare professionals worldwide. The company's dedication to research, development, and clinical collaboration ensures continued success in the field of minimally invasive interventions.

Who are the main competitors of AngioDynamics in the market?

The main competitors of AngioDynamics Inc in the market include Medtronic Inc, Boston Scientific Corporation, and Johnson & Johnson.

In which industries is AngioDynamics primarily active?

AngioDynamics Inc is primarily active in the medical device industry.

What is the business model of AngioDynamics?

AngioDynamics Inc operates as a medical device company, specializing in the design, development, manufacturing, and marketing of medical, surgical, and diagnostic devices used in minimally invasive procedures. The company's business model focuses on providing innovative solutions to healthcare professionals for the treatment of vascular diseases and conditions. AngioDynamics offers a wide range of products, including ablation systems, thrombus management devices, venous access products, and peripheral vascular devices. By delivering high-quality and reliable medical devices, AngioDynamics aims to improve patient outcomes and provide value to healthcare providers.

What is the P/E ratio of AngioDynamics 2024?

The AngioDynamics P/E ratio is -1.7.

What is the P/S ratio of AngioDynamics 2024?

The AngioDynamics P/S ratio is 1.03.

What is the AlleAktien quality score of AngioDynamics?

The AlleAktien quality score for AngioDynamics is 2/10.

What is the revenue of AngioDynamics 2024?

The AngioDynamics revenue is 303.91 M USD.

How high is the profit of AngioDynamics 2024?

The AngioDynamics profit is -184.35 M USD.

What is the business model of AngioDynamics

AngioDynamics Inc. is a leading company in the field of minimally invasive medicine and offers innovative medical technology solutions for vascular diseases, cancer treatment, and interventional radiology. The company operates globally and distributes its products in over 90 countries. The company operates in three main business areas: Vascular Access, Peripheral Vascular, and Oncology. The Vascular Access area includes products such as port systems, catheters, and accessories used to create long-term vascular access for patients requiring repeated blood draws or infusions. The Peripheral Vascular area includes products such as atherectomy systems, thrombectomy systems, and stent systems used for the treatment of peripheral vascular diseases such as atherosclerosis and thrombosis. Oncology offers a wide range of products and systems for cancer treatment, including catheters and port systems. Another important area of AngioDynamics is interventional radiology. The company offers innovative instruments and systems for the diagnosis and treatment of diseases such as liver tumors and prostate enlargement. Products in this area include microwave-assisted tumor ablation systems, needles, catheters, and accessories. AngioDynamics is also a key player in the field of medical imaging. The company provides systems for navigation and visualization of catheters and instruments used in minimally invasive procedures. These products enable physicians to perform precise and safe procedures and offer patients faster recovery. The business model of AngioDynamics is based on the development and marketing of innovative medical solutions that improve the treatment of vascular diseases, cancer, and other diseases. The company invests in research and development to develop new products and technologies that meet the needs of physicians and patients. Additionally, the company collaborates closely with hospitals and medical facilities to ensure rapid adoption and dissemination of its products. AngioDynamics has a strong and diverse product line that enables the company to serve various markets and customers. The company offers high-quality products and solutions that are valued in medical practice worldwide. With its leadership role in research and development of minimally invasive medicine, AngioDynamics is well positioned to continue growing and maintaining its position as a leading company in the industry. Overall, AngioDynamics' business model is focused on providing innovative medical products and solutions that improve the treatment of vascular diseases, cancer, and other diseases. The company operates in multiple business areas and has a strong presence in the global market. With its extensive product line, leadership role in research and development, and close collaboration with hospitals and medical facilities, AngioDynamics is well positioned to maintain its leading role in the industry in the future.

What is the AngioDynamics dividend?

AngioDynamics pays a dividend of 0 USD distributed over payouts per year.

How often does AngioDynamics pay dividends?

The dividend cannot currently be calculated for AngioDynamics or the company does not pay out a dividend.

What is the AngioDynamics ISIN?

The ISIN of AngioDynamics is US03475V1017.

What is the AngioDynamics WKN?

The WKN of AngioDynamics is A0B9A5.

What is the AngioDynamics ticker?

The ticker of AngioDynamics is ANGO.

How much dividend does AngioDynamics pay?

Over the past 12 months, AngioDynamics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, AngioDynamics is expected to pay a dividend of 0 USD.

What is the dividend yield of AngioDynamics?

The current dividend yield of AngioDynamics is .

When does AngioDynamics pay dividends?

AngioDynamics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of AngioDynamics?

AngioDynamics paid dividends every year for the past 0 years.

What is the dividend of AngioDynamics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is AngioDynamics located?

AngioDynamics is assigned to the 'Health' sector.

Wann musste ich die Aktien von AngioDynamics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of AngioDynamics from 10/1/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/1/2024.

When did AngioDynamics pay the last dividend?

The last dividend was paid out on 10/1/2024.

What was the dividend of AngioDynamics in the year 2023?

In the year 2023, AngioDynamics distributed 0 USD as dividends.

In which currency does AngioDynamics pay out the dividend?

The dividends of AngioDynamics are distributed in USD.

All fundamentals about AngioDynamics

Our stock analysis for AngioDynamics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of AngioDynamics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.